First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients☆ - ESMO Open
Bristol might play a role in front-line lung cancer after all | Evaluate
New CheckMate-227 5-Year Data Show Substantial Survival Benefit of Combination Immunotherapy for Metastatic Non–Small Cell Lung Cancer
February 6, 2018 Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus
JTO & JTO CRR on Twitter: "In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival versus chemotherapy in patients w/tumor programmed death-ligand 1 greater than or equal to 1% (primary end point)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
ISPOR 2022: Mixture-Cure Modelling of the Overall Survival Outcomes of Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC) Receiving Nivolumab + Ipilimumab in CheckMate-227
Immunotherapy in Advanced Lung Cancer
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC
ESMO 2022: Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC | Nature Reviews Clinical Oncology
First-line Nivolumab Plus Ipilimumab is Safe
2021 Midyear Review: Non–Small-Cell Lung Cancer | Personalized Medicine in Oncology
Update Confirms 5-Year Survival Benefit With Dual Immune Checkpoint Blockade in NSCLC
Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
🇨🇦🏥🥷 Twitterren: "But not to worry: CHECKMATE-227 is hear to save the day! WOW look at those sweet PFS curves... and independent of PD-L1! Who needed that test anyway when I can
TMB as a Biomarker for NSCLC Therapy: Could New Developments Herald a Resurgence?
Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options
Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC? - ILCN.org (ILCN/WCLC)
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. | Semantic
